59 related articles for article (PubMed ID: 35234695)
1. Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study.
Jin D; Jin K; Chen B; Zhou X; Yuan Q; Zhang Z; Wei Q; Qiu S
Chin Med J (Engl); 2022 Apr; 135(7):820-827. PubMed ID: 35234695
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study.
Qin X; Han C; Zhang H; Dai B; Zhu Y; Shen Y; Zhu Y; Shi G; Ye D
World J Surg Oncol; 2015 May; 13():172. PubMed ID: 25943443
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
Rajan P; Frew JA; Wilson JM; Azzabi AS; McMenemin RM; Stockley J; Soomro NA; Durkan G; Pedley ID; Leung HY
Urol Oncol; 2015 Aug; 33(8):337.e1-6. PubMed ID: 26092557
[TBL] [Abstract][Full Text] [Related]
4. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.
Griffin K; Csizmadi I; Howard LE; Pomann GM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Beebe-Dimmer J; Freedland SJ
Cancer Causes Control; 2019 Mar; 30(3):259-269. PubMed ID: 30701374
[TBL] [Abstract][Full Text] [Related]
5. Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy.
Utsumi T; Suzuki H; Ishikawa H; Wakatsuki M; Okonogi N; Harada M; Ichikawa T; Akakura K; Murakami Y; Tsuji H; Yamada S
Curr Oncol; 2023 Sep; 30(10):8815-8825. PubMed ID: 37887536
[TBL] [Abstract][Full Text] [Related]
6. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
Deek MP; Sutera P; Jing Y; Gao R; Rothman E; Day H; Chang D; Dirix P; Armstrong AJ; Campbell B; Campos FL; Berenguer M; Ramotar M; Conde-Moreno A; Berlin A; Bosetti DG; Corcoran N; Koontz B; Mercier C; Siva S; Pryor D; Ost P; Huynh MA; Kroeze S; Stish B; Kiess A; Trock B; Tran PT; Gillessen S; Sweeney C
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38570239
[TBL] [Abstract][Full Text] [Related]
7. A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients.
Freedland SJ; Nair S; Lin X; Karsh L; Pieczonka C; Potluri R; Brookman-May SD; Mundle SD; Fleming S; Agarwal N
World J Urol; 2023 Dec; 41(12):3535-3542. PubMed ID: 37966506
[TBL] [Abstract][Full Text] [Related]
8. Novel Approaches in the Systemic Management of High-Risk Prostate Cancer.
Gómez-Aparicio MA; López-Campos F; Lozano AJ; Maldonado X; Caballero B; Zafra J; Suarez V; Moreno E; Arcangeli S; Scorsetti M; Couñago F
Clin Genitourin Cancer; 2023 Dec; 21(6):e485-e494. PubMed ID: 37453915
[TBL] [Abstract][Full Text] [Related]
9. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer.
Fang AM; Jackson J; Gregg JR; Chery L; Tang C; Surasi DS; Siddiqui BA; Rais-Bahrami S; Bathala T; Chapin BF
Curr Treat Options Oncol; 2024 Jan; 25(1):66-83. PubMed ID: 38212510
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone.
Akitake N; Shiota M; Obata H; Takeuchi A; Kashiwagi E; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Int; 2018 Sep; 6(3):104-109. PubMed ID: 30140660
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients - A propensity scoring approach.
Nagao K; Matsuyama H; Nozawa M; Hara I; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
Asian J Urol; 2016 Jan; 3(1):33-38. PubMed ID: 29264160
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
Frei K; Schecher S; Daher T; Hörner N; Richter J; Hildebrand U; Schindeldecker M; Witzel HR; Tsaur I; Porubsky S; Gaida MM; Roth W; Tagscherer KE
Int J Cancer; 2024 Mar; 154(6):1082-1096. PubMed ID: 37916780
[TBL] [Abstract][Full Text] [Related]
13. The long-term outcomes of radical prostatectomy for very high-risk prostate cancer pT3b-T4 N0-1 on definitive histopathology.
Kliment J; Elias B; Baluchova K; Kliment J
Cent European J Urol; 2017; 70(1):13-19. PubMed ID: 28461982
[TBL] [Abstract][Full Text] [Related]
14. Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment.
Vaiana AM; Chen Y; Gelfond J; Johnson-Pais TL; Leach RJ; Ramamurthy C; Thompson IM; Morilak DA
Transl Psychiatry; 2023 Oct; 13(1):307. PubMed ID: 37788996
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological profile of COVID-19 in patients with prostate cancer undergoing androgen deprivation therapy at a Brazilian Cancer Center.
Travalini IG; Vergamini LB; Silva ILAFE; Caruso P; Orellana FM; Curado MP; Zequi SC
Einstein (Sao Paulo); 2023; 21():eAO0273. PubMed ID: 37878968
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk evaluation of cardiovascular disease in the newly diagnosed prostate cancer population in China: A nationwide, multi-center, population-based cross-sectional study.
Zhang W; Liu H; Liu M; Ying S; Yuan R; Zeng H; Zhang Z; Han S; Si Z; Hu B; Wen S; Xu P; Yu W; Chen H; Wang L; Lin Z; Dai T; Lin Y; Xu T
Chin Med J (Engl); 2024 Apr; ():. PubMed ID: 38613214
[TBL] [Abstract][Full Text] [Related]
17. Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.
Lévesque E; Labriet A; Hovington H; Allain ÉP; Melo-Garcia L; Rouleau M; Brisson H; Turcotte V; Caron P; Villeneuve L; Leclercq M; Droit A; Audet-Walsh E; Simonyan D; Fradet Y; Lacombe L; Guillemette C
Br J Cancer; 2020 Mar; 122(7):1068-1076. PubMed ID: 32047296
[TBL] [Abstract][Full Text] [Related]
18. Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study.
Lee YHA; Chan JSK; Hui JMH; Tang P; Liu K; Dee EC; Ng K; Tse G; Ng CF
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140773
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.
Aoun F; Bourgi A; Ayoub E; El Rassy E; van Velthoven R; Peltier A
Ther Adv Urol; 2017; 9(3-4):73-80. PubMed ID: 28392836
[TBL] [Abstract][Full Text] [Related]
20. The functional roles of m6A modification in prostate cancer.
Zhang F; Chen F; Wang C; Zhou FH
Proteomics Clin Appl; 2023 Nov; 17(6):e2200108. PubMed ID: 37070355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
